



14 Supplementary Figures



15

16 **Supplementary Figure 1.** 1×10^6 4T1 cells transfected with different plasmids (including Control
 17 (without treating), OE (*IDO1* over expression plasmid), OE-Control (Untreated plasmid for OE),
 18 KD (*IDO1* knock down plasmid), KD-Control (Untreated plasmid for KD)) were injected into the
 19 second left breast pad of 6-week-old female Balb/c mice at day 0. Tumor volume of mice were
 20 measured every 2 days during days 7-21. The mice in each group were euthanized after 21 days of
 21 injection, and the tumor tissues were collected for immunofluorescence staining (IDO). (a) Separate
 22 and integrated tumor growth curves ($n = 5$ mice per group, statistical differences were calculated
 23 using two-way ANOVA with the Geisser-Greehouse correction, match values are stacked into a
 24 subcolumn, data were expressed as means \pm SD in integrated tumor growth curves, * $P < 0.05$, ** P


25 < 0.01, *** $P < 0.001$, **** $P < 0.0001$.) and (b) Images of IDO immunofluorescence staining and
26 corresponding mean fluorescence intensity of 4T1 tumor-bearing mouse after different treated.
27 DAPI was used to stain the nucleus of the cell (blue), and the IDO was stained with anti-IDO
28 antibodies (red) ($n = 3$ biologically independent samples, statistical differences were calculated
29 using two-tailed unpaired Student's t-test, data were expressed as means \pm SD, * $P < 0.05$, ** $P <$
30 0.01, *** $P < 0.001$, **** $P < 0.0001$). Source data are provided as a Source Data file.
31



32

33 **Supplementary Figure 2.** (a) Agarose gel electrophoresis and (b) corresponding quantitative
 34 analysis of MHS nanoparticles at different MH/sgRNA ratios after incubation with serum (10%
 35 volume) for 6 h. Group 0 *i.e.* naked Cas9/sgRNA. ($n = 3$ independent experiments) (c) N_2
 36 adsorption-desorption isotherms and of MH. The inset shows its corresponding total pore volume
 37 and specific surface area. (d) Agarose gel electrophoresis and (e) corresponding quantitative
 38 analysis to evaluate the serum stability of naked Cas9/sgRNA and Cas9/sgRNA reconstituted from
 39 MHS ($n = 3$ independent experiments). (f) SDS-PAGE and (g) corresponding quantitative
 40 analysis to evaluate the serum stability of Cas9/sgRNA and Cas9/sgRNA reconstituted from MHS ($n = 3$
 41 independent experiments). (h) Release of Cas9/sgRNA from MHS. ($n = 3$ independent samples,



42 data were expressed as means \pm SD). (i) UV-vis absorption spectra of 1,3-diphenylisobenzofuran
43 (DPBF) upon US irradiation for prolonged durations. (j) Zeta- potential of LGG and LGG-MHS (n
44 = 3 independent samples, data were expressed as means \pm SD). (k) Agarose gel electrophoresis and
45 (l) corresponding quantitative analysis of the activity of CRISPR/Cas9 nanosystem under different
46 states, including I (DNA Only), II (Cas9/sgRNA + DNA), III (MHS + DNA), IV (MHS + US +
47 DNA), V (LGG-MHS + DNA), VI (LGG-MHS + US + DNA) ($n = 3$ biologically independent
48 experiments). Statistical differences were calculated using two-tailed unpaired Student's t-test for
49 comparisons between two groups, ordinary one-way ANOVA for comparisons more than two
50 groups. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. (m) Representative photographs and
51 (n) corresponding CFU quantitative of MRS agar plates of bacterial activity with various
52 concentrations of MHS in a different time (0, 2, 6, 12 and 24 h) ($n = 3$ independent samples). The
53 experiments for **a**, **c**, **d**, **f**, **k** and **i** were repeated three times independently with similar results.
54 Source data are provided as a Source Data file.
55



56

57 **Supplementary Figure 3.** (a) CLSM images and (b) the corresponding mean fluorescence intensity
 58 analysis of cellular uptake of Cy3-labeled MHS by 4T1 cancer-cell line after coincubation with
 59 different inhibitors ($n = 3$ biologically independent samples) (c) Fluorescence intensity of CLSM
 60 images of 4T1 cells with different treatments ($n = 3$ biologically independent samples) (d) Z-stack


61 CLSM images of 4T1 cells cultured with Cy5.5-labeled MHS nanosystem upon US irradiation for
62 1 and 3 h at 37 °C. The cell nuclei were stained with DAPI (blue), endo/lysosomes were stained
63 with LysoTracker Green (green), and MHS was labeled with Cy5.5 (red) (e) Gating strategies for
64 isolating PI⁺FITC⁺ 4T1 cells. (f) CLSM observation and (g) corresponding PI/ calcein-AM
65 fluorescence intensity ratio of 4T1 cells stained by calcein-AM (green) and PI (red) after various
66 treatments ($n = 3$ biologically independent samples). (h) Western Blot and (i) corresponding
67 quantitative analysis of IFN- γ -stimulated 4T1 cells with various treatments. (I = control, II = US
68 only, III = MH, IV = MH + US, V = MHS, VI = MHS + US) ($n = 4$ biologically independent
69 experiments). (j) *In vitro* gene-editing efficiency in 4T1 cells. DNA sequencing of *IDO1* after
70 various treatments (The representative data of deep sequencing from three independent
71 experiments). (k) Corresponding quantitative analysis of T7E I cleavage after 4T1 cells with MHS
72 and MHS + US treatment ($n = 3$ biologically independent experiments, data were expressed as
73 median). Representative images of three biologically independent samples from each group is
74 shown in **a**, **d** and **f**, and four times each experiment was repeated independently with similar results
75 for **h**. Statistical differences of **b**, **c**, **g** and **i**, were calculated using two-tailed unpaired Student's t-
76 test for comparisons between two groups, Dunnett's multiple comparisons post test for comparisons
77 more than two groups containing group Control, data were expressed as means \pm SD. * $P < 0.05$,
78 ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Source data are provided as a Source Data file.
79



80

81 **Supplementary Figure 4.** (a) Deep sequencing for targeted disruption of *IDO1* locus in control,
 82 US only, MH, MH + US, MHS and MHS + US. (b) Nucleotide deletion and insert distribution
 83 around the cut site of *IDO1* locus in control, US only, MH, MH + US, MHS and MHS + US. The
 84 experiments for **a** and **b** were repeated three times independently with similar results.


85



86

87 **Supplementary Figure 5.** (a-c) The quantitative analysis of HMGB1, CRT and HSP70 on Western
 88 Blot ($n = 4$ biologically independent experiments, data were expressed as means \pm SD). Statistical
 89 differences were calculated using two-tailed paired Student's t-test between two groups, Dunnett's
 90 multiple comparisons post test for comparisons more than two groups containing group Control. * P
 91 < 0.05 , ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. (d-f) Fluorescence intensity of HMGB1, CRT
 92 and HSP70 on CLSM ($n = 3$ biologically independent samples, data were expressed as means \pm SD).
 93 Statistical differences were calculated using two-tailed unpaired Student's t-test between two groups,
 94 Dunnett's multiple comparisons post test for comparisons more than two groups containing group
 95 Control. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. (g) Gating strategies for isolating
 96 CD80⁺CD86⁺ mature DCs. Source data are provided as a Source Data file.


97



98

99 **Supplementary Figure 6.** (a) Representative photographs of MRS agar plates and (b)
 100 corresponding quantitative analysis of bacterial colonization in various organs and tumor of 4T1-
 101 bearing mice in a different time (0, 2, 6, 24, and 72 h) ($n = 3$ biologically independent samples). (c)
 102 Sample correlation test of genes alteration with or without LGG treatment. (d) GO analysis of
 103 differential gene expression profiles based on RNAseq after LGG treatment ($n = 3$ mice per group).
 104 Statistical difference was calculated using Fisher's exact test. (e) Corresponding quantitative
 105 analysis of bacterial colonization in various organs harvested from 4T1-bearing mice at various time
 106 points after injection of MHS, LGG and LGG-MHS on solid MRS agar plates ($n = 3$ biologically
 107 independent samples, data were expressed as median). Source data are provided as a Source Data
 108 file.


109



110

111 **Supplementary Figure 7.** (a) Representative photographs and (b) corresponding CFU count
 112 analysis of MRS agar plates of bacterial colonization in various organs of healthy mice in a month
 113 (1, 3, 7 and 30 days) ($n = 3$ biologically independent samples), Control *i.e.* without any treatment.
 114 (c) HE staining of histological sections of various organs in healthy mice after receiving LGG-MHS
 115 injection within one month (1, 3, 7 and 30 days), Control *i.e.* without any treatment. (d) *In vivo*
 116 hematological indices. Hematological assays of mice at 1, 3, 7 and 30 days after LGG-MHS
 117 injection ($n = 3$ biologically independent samples). Control *i.e.* without any treatment. (e) *In vivo*
 118 liver and kidney function index. Hematological assays of mice at 1, 3, 7 and 30 days after LGG-
 119 MHS injection ($n = 3$ biologically independent samples). Control *i.e.* without any treatment. A
 120 representative image of 3 biologically independent samples from each group is shown in **a** and **c**.


121 Statistical differences for **d** and **e** were calculated using Dunnett's multiple comparisons post test,
122 data were expressed as means \pm SD. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Source
123 data are provided as a Source Data file.
124



125

126 **Supplementary Figure 8.** (a) HE staining of histological sections of healthy mice treated with
 127 different doses of LGG-MHS (PBS, 10 ml/kg, 20 ml/kg, 30 ml/kg, 40 ml/kg. 1 mL LGG-MHS = 1
 128 $\times 10^7$ LGG, 1 mg MHS) and subjected to US irradiation of each organ (The representative imaging
 129 from 3 independent samples). (b) *In vivo* hematological indices. Hematological assays of healthy
 130 mice treated with different doses of LGG-MHS (PBS, 10 ml/kg, 20 ml/kg, 30 ml/kg, 40 ml/kg. 1
 131 mL LGG-MHS = 1 $\times 10^7$ LGG, 1 mg MHS). ($n = 3$ biologically independent samples). (c) *In vivo*
 132 liver and kidney function index. Hematological assays of mice healthy mice treated with different
 133 doses of LGG-MHS (PBS, 10 ml/kg, 20 ml/kg, 30 ml/kg, 40 ml/kg. 1 mL LGG-MHS = 1 $\times 10^7$
 134 LGG, 1 mg MHS) ($n = 3$ biologically independent animals). Statistical differences for **b** and **c** were
 135 calculated using Dunnett's multiple comparisons post test, data were expressed as means \pm SD. * P
 136 < 0.05 , ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Source data are provided as a Source Data file.


137



138

139 **Supplementary Figure 9.** (a) Body weight and (b) survival curves of 4T1-tumor-bearing mice with
 140 different treatment (control, US only, MH, MH + US, MHS, and MHS + US) ($n = 5$ mice per group,
 141 data of mice body weight were expressed as means \pm SD. Statistical differences of survival were
 142 calculated using Log-rank test). (c) HE staining of primary tumor histologic sections after different
 143 treatments. (d) Immunofluorescence images and (e) corresponding of TUNEL assay in primary
 144 tumor tissue after different treatments. DAPI was used to stain the nucleus of the cell (blue) ($n = 3$
 145 biologically independent samples). (f) Corresponding fluorescence intensity of specific proteins
 146 expression after DAMPs (HMGB1, CRT, and HSP70) from tumor tissue. ($n = 3$ biologically
 147 independent samples). (g) Images and (h) corresponding fluorescence intensity of IDO
 148 immunofluorescence staining in primary tumors of 4T1 tumor-bearing mice after various treatments.
 149 DAPI was used to stain the nucleus of the cell (blue), and the IDO was stained with anti-IDO



150 antibodies (red) ($n = 3$ biologically independent samples. (i) Average tumor growth curves after
151 being treated by re-challenge. ($n_{\text{LGG-MHI + US}} = 2$ biologically independent animals, $n_{\text{LGG-MHS + US}} =$
152 4 biologically independent animals). Statistical differences were calculated using two-way ANOVA
153 with the Geisser-Greehouse correction, match values are stacked into a subcolumn. $*P < 0.05$, $**P$
154 < 0.01 , $***P < 0.001$, $****P < 0.0001$. A representative image of three biologically independent
155 samples from each group is shown in **c**, **d** and **g**. Statistical differences for **e**, **f** and **h** were calculated
156 using two-tailed unpaired Student's t-test between two groups, ordinary one-way ANOVA for
157 comparisons more than two groups, data were expressed as means \pm SD. $*P < 0.05$, $**P < 0.01$,
158 $***P < 0.001$, $****P < 0.0001$. Source data are provided as a Source Data file.
159



160

161 **Supplementary Figure 10.** (a) The quantitative analysis of mature DCs in tumor tissue after 24 h
 162 after the first different treatments ($n = 3$ biologically independent samples). (b) The quantification
 163 of CD4⁺ and CD8⁺ T cells in the spleen after 24 h after the first different treatments ($n = 3$
 164 biologically independent samples). (c) The quantitative analysis of Tregs in primary tumor tissue
 165 after 24 h after the first different treatments ($n = 3$ biologically independent samples). (d) The
 166 quantitative analysis of M1, M2 and M1/M2 macrophages ratio in spleen after 24 h after the first
 167 different treatments ($n = 3$ biologically independent samples). (e) Gating strategies for isolating
 168 CD80⁺CD86⁺ mature DCs from tumor tissue. (f) Gating strategies for isolating CD4⁺ and CD8⁺ T
 169 cells from spleen tissue. (g) Gating strategies for isolating Tregs from tumor tissue. (h) Gating


170 strategies for isolating M2 macrophages from spleen tissue. Statistical differences were calculated
171 using two-tailed unpaired Student's t-test in **a**, **b**, **c** and **d**, data were expressed as means \pm SD. **P*
172 < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001. Source data are provided as a Source Data file.
173



174

175 **Supplementary Figure 11.** (a) Different channels of immunofluorescence images and (b)
 176 corresponding positive area quantification of CD3⁺CD4⁺ and CD3⁺CD8⁺ proliferating CTLs in
 177 primary 4T1 tumor tissue sections after different treatments (control, LGG, MHS, LGG-MHS,
 178 MHS+US, LGG-MH+US, LGG-MHI+US and LGG-MHS+US ($n = 3$ biologically independent
 179 samples, data were expressed as means \pm SD). Statistical differences were calculated using two-
 180 tailed unpaired Student's t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Source data
 181 are provided as a Source Data file.


182



183

184 **Supplementary Figure 12.** (a) Representative photographs of MRS agar plates and (b)
 185 corresponding quantitative analysis of bacterial colonization in primary and distal tumor of 4T1-
 186 bearing mice ($n = 3$ biologically independent samples, data were expressed as median). (c)
 187 Individual tumor growth curves of primary tumor after being untreated, treated by LGG, MHS,
 188 LGG-MHS, MHS + US, LGG-MH + US, LGG-MHI + US and LGG-MHS + US ($n = 5$ mice per
 189 group). (c) Digital images and weight statistics of primary and (d) distal tumors of 4T1 tumor-

190 bearing mice at the 21th day after different treatments (control, LGG, MHS, LGG-MHS, MHS +
191 US, LGG-MH + US, LGG-MHI + US and LGG-MHS + US) ($n = 5$ biologically independent
192 samples). (e) Different channels of immunofluorescence images and (f) corresponding positive area
193 quantification of CD3⁺CD4⁺ and CD3⁺CD8⁺ proliferating CTLs in distant 4T1 tumor tissue sections
194 after various treatments, including control, LGG, MHS, LGG-MHS, MHS + US, LGG-MH + US,
195 LGG-MHI + US and LGG-MHS + US ($n = 3$ biologically independent samples). (g) Gating
196 strategies for isolating T cells (CD3⁺CD8⁺CD44⁺CD62L⁻) (Tem) and
197 (CD3⁺CD8⁺CD44⁺CD62L⁺) (Tcm). (h) Corresponding quantification of the effector memory T
198 cells (CD3⁺CD8⁺CD44⁺CD62L⁻) (Tem) and (CD3⁺CD8⁺CD44⁺CD62L⁺) (Tcm) in the spleen after
199 24 h after the first different treatments ($n = 3$ biologically independent samples). (i) Representative
200 photographs and counts of the number of lung metastatic nodules after various treatment (control,
201 LGG, MHS, LGG-MHS, MHS + US, LGG-MH + US, LGG-MHI + US and LGG-MHS + US) (n
202 = 3 biologically independent samples). Representative images of three biologically independent
203 samples from each group is shown in **a**, **e** and **i**. Statistical differences for **c**, **d**, **f**, **h** and **i** were
204 calculated using two-tailed unpaired Student's t-test for comparisons between two groups, ordinary
205 one-way ANOVA for comparisons more than two groups, data were expressed as means \pm SD. * P
206 < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Source data are provided as a Source Data file.
207



208

209 **Supplementary Figure 13.** (a) Uncropped scans of gels in Supplementary Figures 2a. (b)
 210 Uncropped scans of gels in Supplementary Figures 2d. (c) Uncropped scans of gels in
 211 Supplementary Figures 2f. (d) Uncropped scans of blots in Supplementary Figures 3g.

212 **Supplementary Table**

213 **Supplementary Table 1: Corresponding atomic fraction of Fig. 2d.**

	Zn (%)	P (%)	N (%)	C (%)
ZIF-8	1.09	0.01	3.89	95.01
MH	0.95	0.01	2.67	96.37
MHS	3.88	0.56	4.95	90.61

214